New drug combo shows promise for rare protein disease
NCT ID NCT03283917
First seen Mar 04, 2026 · Last updated May 01, 2026 · Updated 9 times
Summary
This early-phase study tested a combination of three drugs (daratumumab, ixazomib, and dexamethasone) in 21 people with AL amyloidosis, a rare disease where abnormal proteins build up in organs. The goal was to find the safest dose and check for side effects. Researchers hope this approach can help control the disease by targeting the abnormal cells that produce these proteins.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT PRIMARY AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.